ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

9:00AM-11:00AM: Abstract Number: 1360

New-Onset Inflammatory Bowel Diseases Among IL-17 Inhibitors-Treated Patients: Results from the Case-Control MISSIL Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1092

NMR-Based Serum Metabolomics, Is It Different in Clinico-Serological Clusters of Idiopathic Inflammatory Myositis?

Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Abstract Number: 1173

No Disease Progression After 36 Months Follow up in the Juvenile Systemic Scleroderma Inception Cohort

Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1234

Noninflammatory Pain Is a Frequent Phenomenon in Rheumatoid Arthritis and Responds Well to Treatment with Sarilumab

RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

9:00AM-11:00AM: Abstract Number: 0997

Novel Shared Antibody Specificities in Ro Antibody Negative Sjögren’s Syndrome

B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 1159

Novel STING1 Mutations Including in the Transmembrane Linker Region Cause STING-associated Vasculopathy with Onset in Infancy (SAVI)

Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1036

Ocular Involvement and Treatment in Sarcodosis. Study of 41 Patients of a Series of 383 Patients from a Single University Hospital

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

9:00AM-11:00AM: Abstract Number: 1044

Ocular Manifestations in Inflammatory Bowel Disease. Study of 1442 Patients from a Single Referral Center

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

9:00AM-11:00AM: Abstract Number: 1043

Ocular Scleral Pathology and Immune-Mediated Inflammatory Diseases. Study of 170 Patients from a Single Universitary Center

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

9:00AM-11:00AM: Abstract Number: PP06

Only in My Dreams Can I Do the Things I Used to Do: Where There Is Research, There Is Hope

Patient Perspectives Poster

9:00AM-11:00AM: Abstract Number: 1281

Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1021

Organ Damage in Systemic Lupus Erythematosus Is Attributable More to Comorbidity (Hypertension) and Less to Socioeconomic Status

Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1122

Osteoarthritis in a Large Integrated Health System Population: 18-Year Retrospective Review

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1121

Osteoarthritis in the Million Veterans Program: Integrating the Electronic Medical Record with Precision Medicine

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1110

Osteoarthritis-Related Knee Inflammation Measured by Ultrasound Is Associated with Performance-Based Measures of Function

Osteoarthritis – Clinical Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].